COMMUNIQUÉS West-GlobeNewswire
-
Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
11/10/2018 - 22:01 -
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States
11/10/2018 - 22:01 -
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
11/10/2018 - 22:01 -
Chimerix to Host Annual Investor Update on October 17, 2018
11/10/2018 - 22:01 -
NSS Labs Announces 2018 Breach Detection Systems Group Test Results
11/10/2018 - 21:52 -
CFN Media Enhances its LA Studio for Exclusive Interviews and CFN Weekly Show
11/10/2018 - 21:40 -
CV Sciences, Inc. to be a Featured Panelist at TheStreet’s Investing Event on October 13th in New York, NY
11/10/2018 - 21:07 -
Eckert & Ziegler BEBIG SA and Eckert & Ziegler Strahlen- und Medizintechnik AG will propose to their shareholders the merger of the two companies
11/10/2018 - 19:31 -
Eckert & Ziegler BEBIG SA et Eckert & Ziegler Strahlen- und Medizintechnik AG vont proposer à leurs actionnaires la fusion entre les deux sociétés
11/10/2018 - 19:31 -
Texas Companies and Universities Bring World’s Largest Algae Technology Conference to The Woodlands
11/10/2018 - 19:08 -
CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C
11/10/2018 - 18:57 -
Pediapharm Announces Closing of Subscription Receipt Offering for Total Gross Proceeds of $62 Million
11/10/2018 - 18:14 -
Virbac : revenue grew by +5.5% at constant exchange rates at the end of September 2018
11/10/2018 - 17:46 -
Virbac : chiffre d'affaires en croissance de +5,5% à taux de change constants à fin septembre 2018
11/10/2018 - 17:46 -
TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the 34th Congress of ECTRIMS
11/10/2018 - 17:00 -
Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
11/10/2018 - 16:47 -
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
11/10/2018 - 16:45 -
OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA
11/10/2018 - 15:36 -
Vital Therapies Provides Strategic Update
11/10/2018 - 15:27
Pages